AstraZeneca stops chronic kidney disease treatment trial early after “overwhelming efficacy”

The pharma company also announced Imfinzi has been approved for small cell lung cancer in combination with chemotherapies

AstraZeneca - AstraZeneca stops trial early for “overwhelming efficacy”

AstraZeneca PLC (LON:AZN) has stopped a late-stage trial of its chronic kidney disease treatment as it showed “overwhelming efficacy”.

An independent committee advised the FTSE 100-listed company to halt the studies for Farxiga, which is already under review to treat patients with heart failure.

READ: AstraZeneca posts negative results for late-stage bladder cancer treatment

AstraZeneca will now initiate discussions with global health authorities regarding early regulatory submissions.

In a note to clients, analysts at Shore Capital said they expect Farxiga to generate US$3bn by 2024.

In a separate announcement, the pharma giant also said that its Imfinzi drug has been approved in the US as a first-line treatment for extensive-stage small cell lung cancer, in combination with chemotherapies.

Imfinzi, which has already been approved for other types of cancer, is expected to generate sales of US$2bn this year and grow to US$4bn by 2024.

AstraZeneca shares rose 1% to 6,858p on Monday morning.

-- Adds analyst comment --

Quick facts: AstraZeneca

Price: 8580 GBX

Market: LSE
Market Cap: £112.59 billion


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



4D Pharma PLC about to start dosing patients in its Phase II trial for COVID-19

4D pharma plc's (LON:DDDD) Duncan Peyton tells Proactive London's Andrew Scott they're focused on live biotherapeutics - a new class of therapeutics which uses bacteria as drugs. ''Even though it's a new area we've made a lot of progress in the five years we've been going ... we've got our...

1 day, 2 hours ago

2 min read